Skip to main content
About the Institute
  • English
  • Français
  • Español

Breadcrumb

  1. Home
  2. Microbiota 6 - March 2019
  3. Fecal transplantation - ready for prime time?
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Microbiota 6 - March 2019
  3. Fecal transplantation - ready for prime time?
Gastroenterology

Fecal transplantation - ready for prime time?

C difficile

Congress review

By Pr. Danny De Looze
Department of Gastroenterology University Hospital Gent, Belgium

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

Photo : Fecal transplantation - ready for prime time?

About this article

Created 26 August 2021
Updated 09 September 2024

Despite the fact that we still do not know all the secrets and mysteries about the gut microbiota, a lot of hope is put on treating GI diseases with intestinal microbiota. Fecal microbiota transplantation seems to be the Holy Grale. But is it? At 2018’s UEGW in Vienna numerous lectures were dedicated to it. An overview.

The ideal donor 

Despite the fact that up until now nobody really knew how to precisely define the normal gut microbiota (“eubiosis”), we do know that high microbial diversity and gene richness are of key importance in the host-microbiota equilibrium. Therefore, the ideal fecal donor should be screened for bacterial richness. A surrogate marker for this property was proposed by Marie Joossen (Leuven, Belgium) who pointed out that the presence of Blastocystis hominis correlates with a higher microbial richness.[1] This finding – if confirmed by others – may change our current practice to avoid carriers of this commensal as fecal donors. Enriching the donor’s microbiota by prebiotics or using multiple donors may also ensure (theoretically) a higher baseline diversity of the donated material. This was also observed by Karakan et al. (Ankara, Turkey) who performed an open trial in ulcerative colitis with an overall complete response rate of 32% which was particularly influenced by a high bacterial diversity in the donated fecal material.

The new brown gold 

Strict adherence to current guidelines for selection of donors for fecal material necessitates the rejection of most donors. Terveer et al. (Leiden, the Netherlands) report that only 3,5% of possible donors are suitable at the end of the line [2]. The main reasons for not being accepted as a donor are: age above 50, high BMI and carrier status of non-pathogenic germs (Blastocystis hominis, Dientamoeba fragilis) and MDROs (multidrug resistant organisms).[2]

Clostridium Difficile 

The main indication for fecal microbiota transplantation remains refractory infection with Clostridium difficile (C. difficile). Ianiro et al. (Rome, Italy) showed, in a retrospective series of 282 C. difficile patients comparing antibiotic treatment and fecal transplant, that this latter treatment resulted in significant shorter hospital stay, significantly lower mortality and specifically less sepsis-related mortality.

Antonio Gasbarrini (Rome, Italy) therefore suggests that the time has come to promote fecal microbiota transplantation as the first line therapy in C. difficile infection.

Expanding the scope of FMT 

Antonio Gasbarrini gave a nice overview of promising indications for fecal micro- biota transplantation. It has been shown that fecal transplants restore the human microbiota better than probiotics after antibiotic-induced dysbiosis in humans. This was also the case following combined chemotherapy and antibiotic induced dysbiosis in the setting of hematological stem cell therapy and in patients with liver cirrhosis receiving antibiotics. Mice models even show evidence for restoration of immune function and intestinal integrity after chemotherapy induced intestinal damage. Therefore, Antonio Gasbarrini makes the case for pre-emptive stool conservation for subsequent autologous fecal microbiota transplantation, e.g. following antibiotic treatment or bone marrow transplantation. In vivo evidence from clinical trials must be awaited before this futuristic but not unrealistic strategy can be implemented. Anyhow, it seems quite logical that collecting one’s own stool for autologous transplantation later in life, is the way to go.

Ulcerative colitis 

In 3 out of 4 published randomized controlled trials fecal microbiota transplantation was superior to placebo in refractory ulcerative colitis (UC) patients [3]. Mean remission rate in these studies, however, was only 25-30 % and Rainer et al. (Graz, Austria) presented a study with similar complete remission rates, showing no added value of administering fresh stool in these patients. Nevertheless, up until now there was no standardized stool transplantation protocol in UC. Remission rates of 30% seem low but to put things in perspective: this is also the remission rate that is achieved with the expensive and widely used biologicals [...]. The importance of colonic microbiota in UC was demonstrated by Herrera-de Guise et al. (Barcelona, Spain) who showed that patients in long-term stable remission (more than 5 years) present with an abundance of Akkermansia muciniphila and Faecalibacterium prausnitzii, similar to healthy controls. These authors even suggest that we should think of a paradigm shift in treating UC: our therapeutic endpoint should perhaps no longer be immune suppression, but we should aim to reach eubiotic microbiota characteristics.

Irritable bowel syndrome 

Irritable bowel syndrome (IBS) is certainly the condition for which the expectations of a cure by fecal microbiota transplantation are very high in both patients and health care practitioners. Still, conflicting results from randomized controlled trials [4, 5] do not currently support a widespread use of this treatment in IBS. Intestinal dysbiosis is present in IBS but a clear causality between these microbial changes and symptoms are lacking. Halkjaer et al. (Copenhagen, Denmark) performed a randomized controlled trial in 52 adult IBS patients; an increase in biodiversity (comparable to the donors) was observed in the patients being actively transplanted.[5] Unfortunately, the placebo group had a significantly better clinical outcome at 3 and 6 months than the patients receiving fecal capsules.[5] In a small cohort of 16 IBS patients, Holster et al. (Orebro, Sweden) were also unable to demonstrate efficacy for fecal microbiota transplant vs. placebo. They also studied rectal sensitivity by means of a barostat and showed no difference between the active and control groups, concluding that changing the microbiota does not contribute to the visceral hypersensitivity in IBS.

Bacterial pills 

Ianiro et al. performed an open label trial in C. difficile infection with a synthetic microbiota suspension (10 patients only) demonstrating efficacy. Khanna et al. (Rochester, USA) have also demonstrated efficacy in prevention of C. difficile infection’s relapse with a non-frozen, lyophilized, orally administrated microbiota restoring drug (RBX7455) in an open-label phase 1 trial. These are promising results that need to be confirmed in large scale randomized trials.

Conclusion

The UEGW 2018 added more insight into the desired eubiotic characteristics of fecal material and the promising new indications for fecal microbiota transplantation that may arise the upcoming years. Up until now C. difficile infection remains the only clear-cut indication for this treatment which is currently not ready for prime time in other conditions.

Explain fecal transplantation to your patients with this dedicated content: 

10.12.2020 Fecal transplant Read more
Sources

1 Tito RY, Chaffron S, Caenepeel C, et al. Population-level analysis of Blastocystis subtype prevalence and variation in the human gutmicrobiota. Gut 2019 Jul;68(7):1180-1189.

2 Terveer EM, van Beurden YH, Goorhuis A, et al. How to establish and run a stool bank. Clin Microbiol Infect 2017 ; 23 : 924-30.

3 Imdad A, Nicholson MR, Tanner-Smith EE, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2018 ; 11:CD012774.

4 Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018 ; 3 : 17-24.

5 Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut 2018 ; 67 : 2107-15.

Tags
Gastroenterology Microbiome Flora
    Focus
    Microbiota 6 - March 2019
    • Overview
      • Microbiota and celiac disease
    • Commented articles
      • Resilience of healthy adult gut microbiota following antibiotic exposure
      • Feeding practices from birth to 12 months: impact on the gut microbiota and the risk of being overweight
    • Congress review
      • Fecal transplantation - ready for prime time?
      • The gut microbiota: issues and challenges in the management of metabolic disorders
    • Press review
      • Proton pump inhibitors modify gut microbiome
      • Gut microbiota involved in the pathogenesis of non-alcoholic fatty liver disease
    Created 26 August 2021
    Updated 09 September 2024

    About this article

    To know more about this topic.

    Main topic

    C difficile

    Content type

    Congress review
    Feeding practices from birth to 12 months: impact on the gut microbiota and the risk of being overweight
    The gut microbiota: issues and challenges in the management of metabolic disorders
    Focus

    Microbiota 6 - March 2019

    Overview

    Microbiota and celiac disease

    Commented articles

    Resilience of healthy adult gut microbiota following antibiotic exposure Feeding practices from birth to 12 months: impact on the gut microbiota and the risk of being overweight

    Congress review

    Fecal transplantation - ready for prime time? The gut microbiota: issues and challenges in the management of metabolic disorders

    Press review

    Proton pump inhibitors modify gut microbiome Gut microbiota involved in the pathogenesis of non-alcoholic fatty liver disease
    Gastroenterology
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more
    20.03.2025

    Entacapone and the gut: a hidden impact on parkinson’s care

    Read the article

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irrita...

    Find out more
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo